Furthermore, a prospective study of dermatologic adverse events in NSCLC patients receiving PD-1 inhibitors found that tumor and skin tissues shared nine T-cell antigens, and it has been speculated that T cells targeting cancer cells may also target normal tissues with shared antigens (47), which may partially explain the correlation between irAEs and PD-1/PD-L1 inhibitor efficacy. This evidence concerns the gene CD274 and non-small cell lung carcinoma.